Patient Demographics in Slow Titration Study

Many patients had other prior treatments including oral opioids, non-opioid medications, spinal cord stimulation, spinal surgery, neuroablation, physical therapy, and IT medications.13,14

14 to 15 years
was the approximate mean duration of pain13
97%
of patients were refractory
to treatment13
80.7 mm
was the mean baseline
VASPI (Visual Analog Scale of
Pain Intensity) score13
80%
of subjects were receiving
intrathecal drugs at the time of
enrollment and required weaning13
93%
were successfully weaned
from intrathecal medications
to systemic analgesics13

pg11HCP_orange_man

Important Safety Information

DRUG INTERACTIONS

  • Formal drug-drug interaction studies were not conducted with PRIALT.
  • The combination of PRIALT with intrathecal opiates has not been studied in placebo-controlled clinical trials and is not recommended.
  • Patients taking concomitant antiepileptics, neuroleptics, sedatives, or diuretics may be at higher risk of depressed levels of consciousness.

MOST COMMON ADVERSE REACTIONS
The most frequently reported adverse reactions (≥25%) in clinical trials (n=1254 PRIALT-treated patients) were dizziness, nausea, confusional state, and nystagmus. Slower titration of PRIALT may result in fewer serious adverse reactions and discontinuations for adverse reactions.
Please see full Prescribing Information, including BOXED Warning, and click here for additional Important Safety Information.

References: 13. Rauck RL, Wallace MS, Leong MS, et al; Ziconotide 301 Study Group. A randomized, double‐blind, placebo‐controlled study of intrathecal ziconotide in adults with severe chronic pain. J Pain Symptom Manage. 2006;31(5):393‐406. 14. Data on file. Jazz Pharmaceuticals, Palo Alto, CA.
Patient Demographics
Efficacy Results
Discontinuation Rates
Adverse Events